Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-05-22
2007-05-22
Le, Long V. (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007800, C435S069100, C435S069200, C424S136100, C424S193100, C530S362000, C530S380000, C530S385000
Reexamination Certificate
active
09716054
ABSTRACT:
Bifunctional inhibitor molecules and methods for their use in the inhibition of protein—protein interactions are provided. The subject bifunctional inhibitor molecules are conjugates of a target protein ligand and a blocking protein ligand, where these two moieties are optionally joined by a linking group. In the subject methods, an effective amount of the bifunctional inhibitor molecule is administered to a host in which the inhibition of a protein—protein interaction is desired. The bifunctional inhibitor molecule simultaneously binds to its corresponding target and blocking proteins to produce a tripartite complex that inhibits the target protein—protein interaction. The subject methods and compositions find use in a variety of applications, including therapeutic applications.
REFERENCES:
patent: 5242810 (1993-09-01), Maraganore et al.
patent: 5382657 (1995-01-01), Karasiewicz et al.
patent: 5457182 (1995-10-01), Wiederrecht et al.
patent: 5830462 (1998-11-01), Crabtree et al.
patent: 5834266 (1998-11-01), Crabtree et al.
patent: 5840733 (1998-11-01), Krantz et al.
patent: 5843440 (1998-12-01), Pouletty et al.
patent: 5869337 (1999-02-01), Crabtree et al.
patent: 5871753 (1999-02-01), Crabtree et al.
patent: 6670348 (2003-12-01), Rosen et al.
patent: 2002/0045570 (2002-04-01), Rosen et al.
patent: WO 91/01743 (1991-02-01), None
patent: WO 94/18317 (1994-08-01), None
patent: WO 95/02684 (1995-01-01), None
patent: WO 95/05389 (1995-02-01), None
patent: WO 95/10302 (1995-04-01), None
patent: WO-95/10302 (1995-04-01), None
patent: WO 96/06111 (1996-02-01), None
patent: WO 96/12796 (1996-05-01), None
patent: WO 96/13613 (1996-05-01), None
patent: WO 97/25074 (1997-07-01), None
patent: WO 97/29372 (1997-08-01), None
patent: WO 98/00171 (1998-01-01), None
patent: WO 98/11437 (1998-03-01), None
patent: WO 98/46270 (1998-10-01), None
patent: WO 98/47002 (1998-10-01), None
patent: WO 98/47916 (1998-10-01), None
patent: WO 99/61055 (1999-12-01), None
Griffith et al., X-ray structure of calcineurin inhibition by the immunophilin-immunosuppressant FKBP12-FK506 complex., Cell, vol. 82., pp. 507-522, Aug. 11, 1995.
Varshavsky., Codiminant interference, antieffects, and multitargets drugs, Proc. Natl. Acad. Sci. USA, vol. 95, pp. 2094-2099, 1998.
Jein et al., J Med Chem., 1994, 37, 2100-2105.
Kuduk et al. Bio & Med Chemistry Letters, 10, 2000, 1303-1306.
Waldmann, Science, vol. 252, Jun. 21, 1991, pp. 1657-1662.
Tockman et al. Cancer Research 52:2711s-2718s, 1992.
Peipp and Valerius, Biochemistry Society Transactions, 2002, vol. 30, part 4, pp. 507-511.
Ivery (Medicinal Research reviews, 2000, 20(6), 452-484).
Al-Obeidi, et al., (1990) “Synthesis and Actions of a Melanotropin Conjugate, Ac-[Nle4, Glu(gamma-4′-hydroxyanilide)5, D-Phe7]α -MSH4×10-NH2, on Melanocytes and Melanoma Cells In Vitro,”Journal of Pharmaceutical Sciencesvol. 79, No. (6):500-504.
Atwell, John L., et al., (1996) “Design and Expression of a Stable Bispecific scFv Dimer With Affinity for Both Glycophorin and N9 Neuraminidase,”Molecular Immunologyvol. 22, No. (17/18):1301-1312.
Belshaw, et al., (1996) “Controlling Protein Association and Subcellular Localization with a Synthetic Ligand that Induces Heterodimerization of Proteins,”Proc. Natl. Acad. Sci. U.S.A.vol. 93:4604-4607.
Bernstein, Kenneth E., et al., (1990) “A Deeply Recessed Active Site in Angiotensin-Converting Enzyme Is Indicated From the Binding Characteristics of Biotin-Spacer-Inhibitor Reagents,”Biochemical and Biophysical Communicationsvol. 167, No. (1):310-316.
Bourdouxhe-Housiaux, Catherine, et al., (1996) “Interaction of DNA-Threading Peptide-Amsacrine Conjugates With DNA and Chromatin,”Anti-Cancer Drug Designvol. 11:509-525.
Brochu, et al., (1992) “Modes of Action and Inhibitory Activities of New Siderophore-β-Lactam Conjugates that use Specific Iron Uptake Pathways for Entry into Bacteria,”Antimicrobial Agents and Chemotherapyvol. 36, No. (10):2166-2175.
Briesewitz, et al., (1999) “Affinity Modulation of Small-Molecule Ligands by Borrowing Endogenous Protein Surfaces,”P.N.A.Svol. 96, No. (5):1953-1958.
Chakraborty, TK., et al., (1995) “Design and Synthesis of a Rapamycin-Based High Affinity Binding FKBP12 Ligand,”Chemistry&Biologyvol. 2:157-161.
Crabtree, Gerald R., et al., (1996) “Three-Part Inventions: Intracellular Signalling and Induced Proximity,”Elsevier Trends Journalpp. 418-422.
Heath, et al., (1986) “Liposome-Mediated Delivery of Pteridine Antifolates to cells in Vitro: Potency of Methotrexate, and its α and γ Substituents,”Biochimica et Biophysica Actavol. 862:72-80.
Holt, et al., (1994) “Structure-Activity Studies of Synthetic FKBP Ligands as Peptidyl-Prolyl Isomerase Inhibitors,”Bioorganic and Medicinal Chemistry Lettersvol. 4, No. (2):315-320.
Kramer, Werner, et al., (1992) “Liver-Specific Drug Targeting by Coupling to Bile Acids,”The Journal of Biological Chemistry, vol. 267, No. (2):18598-18604.
Luengo, et al., (1994) “Synthesis and Structure-Activity Relationships of Macrocyclic FKBP Ligands,”Bioorganic and Medicinal Chemistry Lettersvol. 4, No. (2):321-324.
Lussow, et al., (1996) “Targeting of Antihapten Antibodies to Activated T Cells via an IL-2-Hapten Conjugate Prolongs Cardio Graft Survival,”Trasplantationvol. 62, No. (12):1703-1708.
Maeda, et al., (1997) “Amino Acids and Peptides XXXII: A Biofunctional Poly(Ethylene Glycol) Hybrid of Fibronectin-Related Peptides,”Biochemical and Biophysical Research Communicationsvol. 241:595-598.
Mogre, R.M., et al., (1987) “A New Carbene Based Heterbifunctional Reagent: Photochemical Crosslinking of Aldolase,”FEBS Letters, vol. 221, No. (2):408-414.
Mu, Yu., et al., (1999) “Bioconjugation of Laminin Peptide YIGSR With Poly(Styrene Co-Maleic Acid) Increases Its Antimetastatic Effect on Lung Metastasis of B16-BL6 Melanoma Cells,”Biochemical and Biophysical Research Communications, vol. 255:75-79.
Varshavsky, Alexander, (1998) “Codominant Interference, Antieffectors, and Multitarget Drugs,”Proc. Natl. Acad. Sci. USA, vol. 95:2094-2099.
Varshavsky, Alexander, (1995) “Codominance and Toxins: A Path to Drugs of Neatly Unlimited Selectivity,”Proc. Natl. Acad. Sci. USA, vol. 92:3663-3667.
Zunino, et al., (1984) “Compassion of Antitumor Effects of Daunorubicin Covalently Linked to Poly-L-Amino Acid Carriers,”Eur. J. Cancer Chem. Oncol.vol. 20, No. (3):421-425.
Choi et al. (1996) “Structure of the FKBP12-Rapamycin Complex Interacting with the Binding Domain of Human FRAP.”Science, vol. 273:239-242.
Clardy (1999) “Borrowing to make ends meet.”Proc. Natl. Acad. Sci. USA, vol. 96:1826-1827.
Garboczi et al. (1996) “Structure of the complex between human T-cell receptor, viral peptide and HLA-A2.”Nature, vol. 384:134-141.
Griffith et al. (1995) “X-Ray Structure of Calcineurin Inhibited by the Immunophilin-Immunosuppressent FKBP12-FK506 Complex.”Cell, vol. 82:507-522.
Johnson et al. (1997) “Amino-terminal dimerization of an erythropoietin mimetic peptide results in increased erythropoietic activity.”Chemistry&Biology, vol. 4:939-950.
Kissenger et al. (1995) “Crystal structures of human calcineurin and the human FKBP12-FK506-calcineurin complex.”Nature, vol. 378:641-644.
Klemm et al. (1997) “Rapid targeting of nuclear proteins to the cytoplasm”Current Biology, vol. 7:638-644.
Livnah et al. (1996) “Functional Mimicry of a Protein Hormone by a Peptide Agonist: The EPO Receptor Complex at 2.8Å”Science, vol. 273:464-471.
Riviera et al. (1996) “A humanized system for pharmacologic control of gene expression.”Nature Medicine, vol. 2(9):1028-1032.
Spencer et al. (1993) “Controlling Signal Transduction with Synthetic Ligands.”Scie
Briesewitz Roger
Crabtree Gerald R.
Stankunas Kryn
Wandless Thomas J.
Bozicevic Field & Francis LLP
Cook Lisa V.
Field, Esq. Bret E.
Le Long V.
The Board of Trustees of the Leland Stanford Junior University
LandOfFree
Bifunctional molecules and their use in the disruption of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bifunctional molecules and their use in the disruption of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bifunctional molecules and their use in the disruption of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3807854